Abstract. The group of patients treated with anticoagulants is increasing due to demographic factors and due to an improved risk stratification. Accordingly, more patients undergoing surgical procedures are ...

Abstract. Patients in need of triple anticoagulation are common in daily medical practice. Triple therapy is defined as the intake of oral anticoagulation (vitamin K antagonist (VKA) or a ...

Abstract. Currently the four direct oral anticoagulants (DOAC) Apixaban, Dabigatran, Edoxaban and Rivaroxaban are approved in Switzerland for the following indications: prevention of stroke or systemic embolism in non-...

Abstract. Travel is associated with an on average 3-fold increased risk of venous thromboembolism. In light of the growing number and baseline morbidity of travelers and the mortality and ...

Abstract. Bleeding episodes are the most frequent side effects in anticoagulated patients. With the introduction of the direct oral anticoagulants (DOACs) the risk of intracerebral bleeding has ...

Abstract. Oral anticoagulation with Vitamin K Antagonists (VKA) is an effective therapy within a narrow therapeutic range expressed as INR (International Normalized Ratio). According to the literature, ...

Abstract. About 20 % to 30 % of thromboembolic events are related to cancer. They represent a classical complication in patients with malignancy. Cancer patients diagnosed with thromboembolism do ...

Abstract. Pregnancy is a hypercoagulable state potentially accentuated by additional factors such as age, mode of delivery, presence of co-morbidities and thrombophilia. The risk of venous thromboembolism (VTE) is ...

Abstract. During treatment with direct oral anticoagulants (DOACs) no monitoring of the anticoagulant effect or of plasma drug-levels are usually required. In case of overdose, drug interactions, ...

Abstract. Thrombophilias are hereditary or acquired conditions predisposing patients to thromboembolism. Testing for thrombophilia is commonly performed in patients with venous thromboembolism (...